Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma, Regardless of PD-L1 Expression Status
The Pharma Data
APRIL 16, 2021
.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) (injection for intravenous use), in combination with fluoropyrimidine- and platinum-containing chemotherapy, was approved by the U.S. 5 (OS HR 0.71; 95% CI: 0.61 5 (OS HR 0.71; 95% CI: 0.61 to 0.83; P <0.0001).
Let's personalize your content